Shibuya-ku, Tokyo, Japan, Japan, May 16, 2022, 05:51 /Comserve / -- Inflammatory bowel disease (IBD) is characterized by the inflammation of the gastrointestinal tract. The exact cause of the disease is yet unknown and prevention from the disease can only save an individual.
With COVID-19 resulting in the economic fallout, numerous economies are working on game-changing improvements to protect their employees and clients. While focusing on the ongoing challenges, the leaders are embracing new plans in order to manage and stay afloat in this competitive environment.
Inflammatory bowel disease (IBD) is characterized by the inflammation of the gastrointestinal tract. The exact cause of the disease is yet unknown and prevention from the disease can only save an individual. There are two types of IBD, namely, Crohn’s disease and ulcerative colitis. The global in-vitro inflammatory bowel disease (IBD) market is anticipated to grow with a CAGR of 5.4% over the forecast period, i.e., 2022 – 2031. Factors such as the growing incidences of the disease globally, followed by the increasing awareness about the disease amongst individuals, and the favorable initiatives of the government of nations for the advancements in research in the field of gastro sciences, are anticipated to drive the market growth. The market is estimated to garner a revenue of about USD 2390 Million by the end of 2028, up from close to USD 1640 Million in 2019.
Get the Sample Copy of This Report: https://www.sdki.jp/sample-request-116053
The Final Report will cover the impact analysis of COVID-19 on this industry: Global In-vitro Inflammatory Bowel Disease Diagnostic and Treatment Market Updates and Key-Players Strategies | With Growth, Forthcoming, Business Prospects and Industry Updates Forecast | 2031 (Trending Report With Imact of Covid19)
The global in-vitro inflammatory bowel disease (IBD) market is segmented by numerous segments, which include segmentation by product, disease type, disease stage, test type, patient demography, end user, test method, and by region. The market is segmented by product into assays/biomarkers and analyzers, out of which, the assays/biomarkers segment is anticipated to grow with the highest CAGR of close to 6% and also hold the highest market share during the forecast period. Moreover, the market is also segmented on the basis of test type into blood tests, stool tests, antibody tests, and biopsy. Out of these, the blood tests segment is anticipated to hold the highest market share and also attain a market revenue of around USD 930 Million by the end of 2028.
The global in-vitro inflammatory bowel disease (IBD) market is segmented on the basis of region into North America, Europe, Asia Pacific, Latin America and Middle East & Africa region, out of which, the market in North America is anticipated to garner the largest market revenue of USD 1070 Million approximately by the end of 2028, up from about USD 720 Million in the year 2019.
Fill This Form and get the Sample Copy of This Report: https://www.sdki.jp/sample-request-116053
The Final Report will cover the impact analysis of COVID-19 on this industry: Global In-vitro Inflammatory Bowel Disease Diagnostic and Treatment Market Updates and Key-Players Strategies | With Growth, Forthcoming, Business Prospects and Industry Updates Forecast | 2031 (Trending Report With Imact of Covid19)
Some of the prominent industry leaders in the global in-vitro inflammatory bowel disease (IBD) market that are included in our report are DiaSorin S.p.A., American Laboratory Products Company, Ltd. (d/b/a ALPCO Diagnostics), Quidel Corporation, CerTest Biotec, S.L., BUHLMANN Laboratories AG, BioSystems S.A., Inova Diagnostics, Inc. (Werfen), and others.
The dynamic nature of business environment in the current global economy is raising the need amongst business professionals to update themselves with current situations in the market. To cater such needs, Shibuya Data Count provides market research reports to various business professionals across different industry verticals, such as healthcare & pharmaceutical, IT & telecom, chemicals and advanced materials, consumer goods & food, energy & power, manufacturing & construction, industrial automation & equipment and agriculture & allied activities amongst others.
For more information, please contact:
Lauren BrownShibuya Data Count
Email: sales@sdki.jp
Tel: + 81 50 50509159
Related Links
https://www.sdki.us/